Literature DB >> 20566409

A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats.

Xu-Feng Zhang1, Char-Chang Shieh, Mark L Chapman, Mark A Matulenko, Ahmed H Hakeem, Robert N Atkinson, Michael E Kort, Brian E Marron, Shailen Joshi, Prisca Honore, Connie R Faltynek, Douglas S Krafte, Michael F Jarvis.   

Abstract

Activation of sodium channels is essential to action potential generation and propagation. Recent genetic and pharmacological evidence indicates that activation of Na(v)1.8 channels contributes to chronic pain. Herein, we describe the identification of a novel series of structurally related pyridine derivatives as potent Na(v)1.8 channel blockers. A-887826 exemplifies this series and potently (IC(50)=11nM) blocked recombinant human Na(v)1.8 channels. A-887826 was approximately 3 fold less potent to block Na(v)1.2, approximately 10 fold less potent to block tetrodotoxin-sensitive sodium (TTX-S Na(+)) currents and was >30 fold less potent to block Na(V)1.5 channels. A-887826 potently blocked tetrodotoxin-resistant sodium (TTX-R Na(+)) currents (IC(50)=8nM) from small diameter rat dorsal root ganglion (DRG) neurons in a voltage-dependent fashion. A-887826 effectively suppressed evoked action potential firing when DRG neurons were held at depolarized potentials and reversibly suppressed spontaneous firing in small diameter DRG neurons from complete Freund's adjuvant inflamed rats. Following oral administration, A-887826 significantly attenuated tactile allodynia in a rat neuropathic pain model. Further characterization of TTX-R current block in rat DRG neurons demonstrated that A-887826 (100nM) shifted the mid-point of voltage-dependent inactivation of TTX-R currents by approximately 4mV without affecting voltage-dependent activation and did not exhibit frequency-dependent inhibition. The present data demonstrate that A-887826 is a structurally novel and potent Na(v)1.8 blocker that inhibits rat DRG TTX-R currents in a voltage-, but not frequency-dependent fashion. The ability of this structurally novel Na(v)1.8 blocker to effectively reduce tactile allodynia in neuropathic rats further supports the role of Na(v)1.8 sodium channels in pathological pain states. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566409     DOI: 10.1016/j.neuropharm.2010.05.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  Injury-induced HDAC5 nuclear export is essential for axon regeneration.

Authors:  Yongcheol Cho; Roman Sloutsky; Kristen M Naegle; Valeria Cavalli
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

2.  PF-06526290 can both enhance and inhibit conduction through voltage-gated sodium channels.

Authors:  Lingxin Wang; Shannon G Zellmer; David M Printzenhoff; Neil A Castle
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

3.  Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review.

Authors:  D P Roberson; A M Binshtok; F Blasl; B P Bean; C J Woolf
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 4.  The role of sodium channels in chronic pain.

Authors:  Simon R Levinson; Songjiang Luo; Michael A Henry
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

5.  Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation.

Authors:  Lingxin Wang; Shannon G Zellmer; David M Printzenhoff; Neil A Castle
Journal:  Br J Pharmacol       Date:  2015-10-15       Impact factor: 8.739

6.  A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability.

Authors:  Claire Elizabeth Payne; Adam R Brown; Jonathon W Theile; Alexandre J C Loucif; Aristos J Alexandrou; Mathew D Fuller; John H Mahoney; Brett M Antonio; Aaron C Gerlach; David M Printzenhoff; Rebecca L Prime; Gillian Stockbridge; Anthony J Kirkup; Anthony W Bannon; Steve England; Mark L Chapman; Sharan Bagal; Rosemarie Roeloffs; Uma Anand; Praveen Anand; Peter J Bungay; Mark Kemp; Richard P Butt; Edward B Stevens
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

7.  Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Front Pharmacol       Date:  2011-10-04       Impact factor: 5.810

8.  Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.

Authors:  Annamaria De Luca; Michela De Bellis; Filomena Corbo; Carlo Franchini; Marilena Muraglia; Alessia Catalano; Alessia Carocci; Diana Conte Camerino
Journal:  Neuromuscul Disord       Date:  2011-07-29       Impact factor: 4.296

9.  Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons.

Authors:  Elisabetta Coppi; Federica Cherchi; Irene Fusco; Paola Failli; Alessia Vona; Ilaria Dettori; Lisa Gaviano; Elena Lucarini; Kenneth A Jacobson; Dilip K Tosh; Daniela Salvemini; Carla Ghelardini; Felicita Pedata; Lorenzo Di Cesare Mannelli; Anna Maria Pugliese
Journal:  Pain       Date:  2019-05       Impact factor: 7.926

10.  Effect of amitriptyline on tetrodotoxin-resistant Nav1.9 currents in nociceptive trigeminal neurons.

Authors:  Jingyao Liang; Xiaoyan Liu; Jianquan Zheng; Shengyuan Yu
Journal:  Mol Pain       Date:  2013-06-22       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.